© 2021 MJH Life Sciences and Psychiatric Times. All rights reserved.
© 2021 MJH Life Sciences™ and Psychiatric Times. All rights reserved.
March 05, 2021
A study finds that testing genetic variations can predict outcomes and medication blood levels in patients with depression.
March 04, 2021
How often do your patients share with you the positive and negative effects of medications?
February 16, 2021
As we learn about the effect of COVID-19 on patients with bipolar and other psychiatric disorders, clinicians should be prepared to ask questions to uncover new syndromic behaviors.
February 15, 2021
Why are serum levels so important?
February 11, 2021
Research on a new kind of cannabis treatment prepares to move forward.
February 04, 2021
As physicians first, psychiatrists must consider the big picture, without reflexive and thoughtless prescriptions for psychotropics—even if many, including medical professionals, assume that is all we do.
January 20, 2021
Nearly half of the prescriptions for benzodiazepine among older adults are potentially inappropriate, so how best to do no harm?
As our knowledge about herbal cannabis, the endocannabinoid system, and cannabinoid pharmacology expands, should psychiatrists discuss these issues with their patients?
January 19, 2021
Although botulinum toxin does not have regulatory approval for the treatment of depression in the United States, some reports indicate neurotoxin treatment may mitigate symptoms.
January 15, 2021
Be on the lookout for these novel psychoactive substances.